Sticky CPI and Pharma Tariffs Compound Tech Pain for MSCI World ETF

The iShares MSCI World ETF plunged 4% as AI stocks tumbled, US inflation accelerated to 4.2%, and new tariffs on patented drugs added pressure. Rate cuts now expected in 2027.

A sharp selloff in artificial-intelligence stocks, a surprisingly hot inflation print, and fresh tariffs on patented medicines have converged to batter the iShares MSCI World ETF, wiping out roughly 4% over the past seven trading days. The fund closed at $197.44 on June 10, after losing 1.55% of its net asset value in a single session. That move was no outlier: the Nasdaq Composite tumbled 2.0% on the day, the S&P 500 slid 1.6%, and rising oil prices linked to US-Iran tensions added to the jitters.

Information technology, which makes up 29.79% of the portfolio, bore the brunt of the damage. Financials account for 15.57% and industrials for 11.36%, but the fund’s heavy 72.27% allocation to US equities means any American-led tech rout hits it especially hard. The net asset value ended June 10 at $197.27, with the market price trading at a tiny 0.09% premium — a sign that investor sentiment, while weak, did not spiral into panic selling.

Inflation pushes rate cuts further into the distance

The selloff was amplified by macro data that gave the Federal Reserve little room for dovishness. US consumer prices rose 4.2% year-on-year in May, accelerating from 3.8% in April. Core inflation also ticked up to 2.9%. Those figures arrived as Kevin Warsh, who took the helm of the Fed on May 22, prepares for his first FOMC meeting on June 16-17.

The labour market adds to the pressure. Nonfarm payrolls increased by 172,000 in May, while the unemployment rate held steady at 4.3%. Goldman Sachs responded by scrapping all rate-cut expectations for 2026, pushing the first reduction to June 2027. With the federal funds rate stuck at 3.50-3.75% since March, growth-dependent tech stocks remain particularly vulnerable. The ETF’s P/E ratio stood at 25.70 and its price-to-book at 3.99 as of June 9, a rich valuation that leaves it exposed to rising discount rates.

Pharmaceutical tariffs add a structural headwind

A presidential executive order signed on April 2 has introduced a 15% tariff on patented pharmaceutical products from the European Union, Japan, South Korea, Switzerland and Liechtenstein. Companies without specific agreements face a standard rate of 100% starting September 29. The MSCI World index has heavy weightings in European and Japanese drugmakers, so the tariff directly raises production costs and clouds earnings visibility for a sector that is already sensitive to interest-rate changes.

Performance and positioning in context

Despite the recent slide, the fund’s net-asset-value total return for 2026 still stood at 7.98% through June 9. The current NAV of $197.27 is well above the 52-week low of $162.91, though roughly 4% below the year’s high of $206.01. The 12-month distribution yield comes to 1.34%.

The ETF tracks the MSCI World Index with 1,285 positions drawn solely from developed markets; emerging markets are excluded. Its expense ratio of 0.24% sits between the cheaper iShares Core MSCI Total International Stock ETF (IXUS, 0.07%) and the broader iShares MSCI ACWI ETF (0.32%). On June 10, ACWI fell 1.65% and IXUS lost 1.64%, underscoring how the MSCI World’s tech concentration magnifies downside in a risk-off environment.

With the FOMC meeting next week and further PPI data due shortly, the fund’s sensitivity to both rate expectations and sector-specific tariffs is unlikely to fade. The RSI has drifted to 42.8, signalling that momentum has stalled — a period of consolidation may be needed before the next directional move emerges.